Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
Efinopegdutide and BAC Water Mix

Efinopegdutide Reconstitution Calculator

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example Efinopegdutide Titration Schedule

ParameterDetails
Phase 2a schedule2.4 → 5 mg (wk 4) → 10 mg (wk 8)
Phase 2b doses4 / 7 / 10 mg once weekly
Duration24–52 weeks (trials)
Half-lifeProlonged (PEGylated peptide)

Investigational. The molecule is PEGylated (not an Fc fusion); in Phase 2a it reduced liver fat by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg.

Possible vial strengths:

What Is It?

Efinopegdutide

GLP-1 / glucagon dual agonist in metabolic research.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix Efinopegdutide

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

Efinopegdutide Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

Efinopegdutide is an investigational GLP-1/glucagon receptor co-agonist, which means it targets two metabolic hormone pathways at once. Search interest around it is tied strongly to liver fat, NASH/MASH research, and metabolic disease rather than only scale weight.
Efinopegdutide was originally developed by Hanmi and later licensed to Merck for development in NASH/MASH. Older or technical sources may call it HM12525A or MK-6024, so a calculator page should connect all names clearly for readers.
Efinopegdutide has FDA Fast Track designation for NASH, but Fast Track is not the same as approval. Current public trial records center on Phase 2 and Phase 2b studies, so a Phase 3 search should be handled as pipeline curiosity rather than confirmed approved-drug information.
Some efinopegdutide studies compare it with semaglutide because researchers want to understand whether adding glucagon receptor activity changes liver-fat outcomes. That comparison is about clinical research design, not a claim that efinopegdutide is interchangeable with approved semaglutide products.
For research math only, concentration equals peptide amount divided by final liquid volume. For example, if 20 mg of efinopegdutide research material were brought to a final volume of 2 mL, the concentration would be 10 mg/mL; a 4 mg research amount would equal 0.40 mL, or 40 units on a U-100 scale. This is calculator math only, not a dosing protocol.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

About the author

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides